Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
Abdulrahman Nasiri, Assistant Professor at Imam Muhammad ibn Saud Islamic University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Proud to share our newly published review in Technology in Cancer Research and Treatment: ‘Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Induction: The End of Story or Not Yet?
For years, the Day 14 bone marrow biopsy (D14 BMB) has guided AML treatment decisions, where less than five percent blasts strongly predicted complete remission following standard seven plus three induction.
However, as the treatment landscape shifts toward targeted therapies, we must re-evaluate this gold standard.
In our review, we explore:
- Evolving Kinetics: Novel agents like venetoclax induce slower blast clearance, meaning traditional D14 assessments may now be premature.
- Cellularity as a marker: Hypocellularity (less than twenty percent) remains a crucial, independent predictor of superior overall survival.
- The re-induction dilemma: Second-course therapy for persistent blasts increases remission rates but does not consistently translate to an overall survival benefit and carries significant morbidity risks.
- The shift to mrd: High-sensitivity Measurable Residual Disease (MRD) monitoring is increasingly becoming the standard for precise, long-term prognostic evaluation and risk stratification.
Our key takeaway: D14 BMB is not obsolete, but it must now be integrated into a risk-adapted framework that accounts for specific treatment modalities and MRD status.”
Title: Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Induction: The End of Story or Not Yet?
Authors: Mostafa F. Mohammed Saleh, Abdulrahman Nasiri, Ahmed Abdrabou, Ali Alahmari, Syed O. Ahmed, Ayman Saad, Mahmoud Aljurf
Read Full Article on Sages Journals
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 26, 2026, 17:17Ajigbotosho Barakat: Leg Strength as a Key to Healthy Aging
-
Apr 26, 2026, 17:02Francisco Chacón-Lozsán: Limited Evidence Methylene Blue in Vasoplegic Shock
-
Apr 26, 2026, 16:57Gopal Patidar: Key Areas of Haemovigilance in ISBT Transfusion Today
-
Apr 26, 2026, 16:56Cathy Harrison: Oral Health in Older Adults Assessing the Impact of Ageing, Heart Failure, and Social Isolation
-
Apr 26, 2026, 15:08Andreas Ejlegård: Rebalancing Thrombosis and Hemostasis Through Mechanistic Innovation
-
Apr 26, 2026, 14:55Vanessa Simioni Faria: Precision Anticoagulation and Expanding Donor Frontiers
-
Apr 26, 2026, 14:52Flora Peyvandi: Results from the PROMISE Study Predicting Recurrent Stroke in Intracranial Atherosclerotic Stenosis
-
Apr 26, 2026, 14:40Rucha Patil: Key Scientific and Collaborative Moments at WFH 2026
-
Apr 26, 2026, 14:34Hadi Mohamad Abu Rasheed: Strengthening the Link Between Air Pollution and Cancer Prevention Through Global Collaboration